Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 231

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 231
---
               | 12 months of fixed compensation as of thedate of leaving office+12 months of most recent individual variablecompensation received prior to leavingoffice | 12 months of fixed compensation as of date ofleaving office+12 months of most recent individual variablecompensation received prior to leavingoffice(e)                        | /                                                              |
| Top-up pension(c)                     | /                                                                                                                                                        | /                                                                                                                                                                              | Annual contribution of up to 25%of reference compensation      |
| Performance share plansnot yet vested | Forfeited in full                                                                                                                                        | Rights retainedpro ratato period ofemployment within Sanofi(f)                                                                                                                 | Rights retainedpro ratato periodof employment within Sanofi(f) |

(a) The amount of the termination benefit is reduced by any indemnity received as consideration for the non-compete undertaking, such that the aggregate amount of those two benefits may never exceed two years of total fixed and variable compensation. (b) The Board of Directors may decide to release the Chief Executive Officer from the non-compete undertaking for some or all of the 12-month period. In that case, the non-compete indemnity would not be due, or would be scaled down proportionately. (c) Defined-contribution pension plan, within the scope of Article 82 of the French General Tax Code. Subject to fulfillment of the performance condition, assessed annually. (d) Subject to fulfillment of the performance condition assessed over the three financial years preceding departure from office, as described above. (e) Subject to the Board of Directors enforcing the non-compete undertaking, the amount of the termination benefit is reduced by any indemnity received as consideration for the non-compete undertaking, such that the aggregate amount of those two benefits may never exceed two years of total fixed and variable compensation. (f) In this case, the Chief Executive Officer remains subject to the terms of the plans, including the performance conditions and the non-compete clause. Policy to recover erroneously-awarded compensation (“clawback”) In 2023, the NASDAQ listing rules were amended to include Rule 5608, in application of Section 10D-1 of the Securities Exchange Act of 1934 which requires listed companies to implement a c lawback policy. On October 26, 2023, our Board of Directors adopted a clawback policy under which Sanofi must, within a reasonable time- frame, recover the portion of the Chief Executive Officer’s variable compensation (cash-based or equity-based) that is wholly or partly contingent on the attainment of